Evidence-Based Integrative Cardiology

Abstract

Integrative cardiology has accumulated a surprisingly robust evidence base over the past two decades, driven partly by the high global burden of cardiovascular disease and partly by structural features of cardiology that make integrative interventions particularly tractable: well-validated clinical endpoints, a long history of lifestyle-intervention trials, and a cardiology research community that has been relatively open to rigorous evaluation of non-pharmacological approaches. The Ornish lifestyle-intervention work, the Manchanda post-MI yoga trials, and the growing Terminalia arjuna clinical base together anchor a field that now has evidence for specific cardiovascular indications approaching the level required for formal clinical-guideline inclusion. We consolidated 88 peer-reviewed clinical studies published between 2014 and 2024 evaluating integrative interventions in adult cardiology populations. Studies were grouped into five indication frames: IC1 (hypertension management), IC2 (coronary artery disease and lipid management), IC3 (heart failure integrative adjuncts), IC4 (arrhythmia prevention and autonomic regulation), and IC5 (secondary prevention post-MI). Each frame was scored on the Integrative Cardiology Evidence Index (ICEI), a weighted composite across clinical effect size, mechanistic evidence, long-term outcome data, safety in concurrent therapy, and translational readiness. Hypertension (IC1) and secondary prevention (IC5) scored highest at ICEI 0.838 and 0.806. Our reading is that integrative cardiology has reached a state of evidence maturity where several of its interventions deserve formal first-line or strongly-adjunctive positioning in clinical-guideline recommendations.